Nordea Investment Management AB Increases Position in Pediatrix Medical Group, Inc. (NYSE:MD)

Nordea Investment Management AB increased its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 51.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 263,633 shares of the company’s stock after acquiring an additional 89,739 shares during the period. Nordea Investment Management AB’s holdings in Pediatrix Medical Group were worth $3,504,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC increased its holdings in shares of Pediatrix Medical Group by 25.6% in the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after purchasing an additional 622 shares during the period. Quarry LP increased its stake in Pediatrix Medical Group by 54.1% in the 3rd quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after buying an additional 1,662 shares during the period. CWM LLC raised its position in Pediatrix Medical Group by 134.0% during the 3rd quarter. CWM LLC now owns 6,427 shares of the company’s stock worth $74,000 after buying an additional 3,681 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Pediatrix Medical Group in the 2nd quarter worth $72,000. Finally, FMR LLC lifted its stake in shares of Pediatrix Medical Group by 220.6% in the 3rd quarter. FMR LLC now owns 9,841 shares of the company’s stock worth $114,000 after acquiring an additional 6,771 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

Insider Transactions at Pediatrix Medical Group

In related news, EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the transaction, the executive vice president now owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the sale, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on MD shares. Jefferies Financial Group boosted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft upped their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. UBS Group increased their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. StockNews.com upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Macquarie began coverage on shares of Pediatrix Medical Group in a report on Monday, December 16th. They issued an “outperform” rating and a $18.00 price target for the company. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $16.25.

Pediatrix Medical Group Trading Down 2.1 %

Shares of MD stock opened at $12.46 on Friday. The stock has a market cap of $1.07 billion, a P/E ratio of -4.07, a P/E/G ratio of 2.00 and a beta of 1.58. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. Pediatrix Medical Group, Inc. has a fifty-two week low of $6.62 and a fifty-two week high of $16.41. The business has a fifty day simple moving average of $14.35 and a 200-day simple moving average of $11.54.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same period last year, the firm posted $0.29 EPS. On average, analysts forecast that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current fiscal year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.